ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

ARGX Argen X SE

349,20
12,10 (3,59%)
23 Abr 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Argen X SE ARGX Euronext Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
12,10 3,59% 349,20 12:40:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
343,90 341,20 350,60 349,20 337,10
mais cotações »

Notícias Recentes

Data Hora Fonte Título
16/04/202402:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/03/202403:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/03/202417:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/03/202403:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07/03/202418:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/02/202403:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/02/202403:00GLOBEargenx to Present at Upcoming Investor Conferences
22/02/202403:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/02/202403:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/01/202403:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/01/202403:00GLOBEargenx Highlights 2024 Strategic Priorities
02/01/202403:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202303:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202303:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202309:40GLOBEargenx Announces European Commission Approval of..
01/11/202303:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
31/10/202303:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202302:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/09/202302:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/09/202302:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/08/202302:00GLOBEargenx to Present at Upcoming Investor Conferences
27/07/202302:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/07/202317:30GLOBEargenx announces closing of global offering
20/07/202302:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/07/202318:58GLOBEargenx announces full exercise of underwriters’ option to..
18/07/202322:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/07/202317:01GLOBEargenx announces launch of proposed global offering
17/07/202302:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30/06/202310:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
20/06/202319:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20/06/202302:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
31/05/202302:00GLOBEargenx to Present at Upcoming Investor Conferences
04/05/202302:00GLOBEargenx Reports First Quarter 2023 Financial Results and..
03/05/202317:01GLOBEargenx announces results of Annual General Meeting of..
02/05/202302:00GLOBEargenx to Present at BofA Securities 2023 Health Care..
27/04/202302:00GLOBEargenx to Report First Quarter 2023 Financial Results and..

Seu Histórico Recente

Delayed Upgrade Clock